<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14215">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921828</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-Celgene-JP-PMS-002</org_study_id>
    <nct_id>NCT02921828</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy of Pomalyst速 Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg</brief_title>
  <official_title>Pomalyst速Capsules Special Use-results Surveillance (All-case Surveillance)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Planned enrollment period One year (The planned number of patients to be enrolled is
           set to 400 patients.) Since all patients who are prescribed with Pomalyst are
           registered in RevMate速, enrollment using the Registration Form of the surveillance will
           be completed at the time when the planned number of patients to be enrolled is reached.
           During a period until conditions for approval are removed, a system enabling to
           retrospectively collect appropriate information based on patient data from RevMate速
           will be, as necessary, maintained.

        2. Planned duration of the surveillance Anticipated to be 2 years and 6 months from the
           start date of release of Pomalyst
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event (AE)</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants with adverse events</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1121</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Multiple myeloma patients who received Pomalyst</arm_group_label>
    <description>Among relapsed or refractory multiple myeloma patients, all patients who received Pomalyst will be targeted in this surveillance.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Among relapsed or refractory multiple myeloma patients, all patients who received Pomalyst
        will be targeted in this surveillance.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Among relapsed or refractory multiple myeloma patients, all patients who received
             Pomalyst will be targeted in this surveillance.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoko Matsui</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shinko Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>651-0072</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 30, 2016</lastchanged_date>
  <firstreceived_date>September 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pomalyst</keyword>
  <keyword>Teratogenicity</keyword>
  <keyword>bone marrow suppression</keyword>
  <keyword>thromboembolism</keyword>
  <keyword>peripheral neuropathy</keyword>
  <keyword>infection</keyword>
  <keyword>tumour lysis syndrome</keyword>
  <keyword>somnolence</keyword>
  <keyword>depressed level of consciousness</keyword>
  <keyword>confusion</keyword>
  <keyword>fatigue</keyword>
  <keyword>dizziness</keyword>
  <keyword>acute renal failure</keyword>
  <keyword>heart failure</keyword>
  <keyword>arrhythmia</keyword>
  <keyword>interstitial pneumonia</keyword>
  <keyword>hypersensitivity</keyword>
  <keyword>hepatic function disorder</keyword>
  <keyword>jaundice</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
